Vad ska jag vlja fr behandling
Retatrutide is currently being studied for several metabolic conditions, including: Cardiovascular disease Chronic lower back pain Knee osteoarthritis Obesity and chronic weight management Obstructive sleep apnea Type 2 diabetes Like other incretin-based drugs, retatrutide is given as a weekly injection during clinical trials
3,5 Whereas injectable semaglutide achieved 15% mean weight loss at 68 weeks in the Semaglutide Treatment Effect in People with obesity (STEP-1) study, it requires subcutaneous administration
A 31-gauge needle works for leaner individuals but flows more slowly
However, its important to note that these comparisons come from different study populations and time periods
Reflection on the Ongoing Journey At this point, Ive lost 18 pounds, and Im feeling so much better than when I started